Wells Fargo upgrades Editas Medicine to Overweight, targets $6
Wells Fargo upgraded Editas Medicine to Overweight and set a $6 price target, from an Equal Weight rating.
Story updates
03:36:05 PM UTC
SquawkNews
Ratings actions from Benzinga
03:36:45 PM UTC
SquawkNews
Editas Medicine Price Target Raised to $6.00/Share From $4.00 by Wells Fargo
03:36:50 PM UTC
SquawkNews
Editas Medicine Raised to Overweight From Equal-Weight by Wells Fargo